Form 4: Sutro Biopharma Director Joseph M. Lobacki Acquires 35,000 Stock Options

Director Joseph M. Lobacki reports acquisition of 35,000 stock options in Sutro Biopharma, Inc.

Summary

• On June 6, 2024, Joseph M. Lobacki, a director of Sutro Biopharma, Inc., acquired 35,000 stock options.
• The exercise price of these options is $3.76.
• The options vest monthly starting July 6, 2024, at a rate of 8.33% of the total award.
• The options will be fully vested by the earlier of the issuer's 2025 annual stockholders meeting or June 6, 2025, contingent upon continued service to the issuer.
• The expiration date for these options is June 6, 2034.

Sentiment

Score: 5

Explanation: Neutral sentiment as it is a standard disclosure of stock option grants.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule implies continued service of the director to the company.

Industry Context

This is a standard SEC filing related to insider transactions, common in publicly traded companies. It provides transparency regarding the holdings and transactions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a director may have a slightly positive impact on shareholder sentiment.

Key Dates